Sydney, Jan 7, 2026, 17:44 AEDT — Market closed
- 4DMedical shares closed up 11.9% after the company flagged a new U.S. academic hospital rollout
- UC San Diego Health started CT:VQ on introductory pricing through March 31, before full terms
- Traders now watch follow-on U.S. wins and the late-February interim report window
Shares of 4DMedical Ltd ASX:4DX climbed 11.9% to close at A$4.69 on Wednesday after the firm said UC San Diego Health had adopted its CT:VQ lung imaging software for clinical use. About 12.8 million shares traded, MarketScreener data showed.
The contract adds a fourth U.S. academic medical centre — a university-linked teaching hospital — to deploy CT:VQ since the product won U.S. Food and Drug Administration clearance in August, sharpening investor focus on commercial traction. UCSD will use introductory pricing through March 31 before moving to full commercial terms, the company said. Jonathan Chung, chief of cardiothoracic imaging at UC San Diego Health, said CT:VQ enables “functional ventilation and perfusion evaluation layered on top of traditional inspiratory and expiratory CT”, while CEO Andreas Fouras called the adoption “another powerful validation”. ASX Announcements
Ventilation-perfusion imaging maps how air and blood move through the lungs, a test hospitals have typically run using nuclear medicine VQ scans that rely on radioactive tracers. 4DMedical says CT:VQ offers a contrast-free alternative and slots into existing CT workflows, which investors view as a potential lever for wider uptake.
UC San Diego Health is regularly ranked among the top U.S. centres for pulmonology and lung surgery, the company said, making it a high-profile reference site for physician training and clinical validation. 4DMedical said it is using deployments at major U.S. centres to support broader adoption and access to reimbursement pathways.
The move outpaced the broader market, with the S&P/ASX 200 closing up 0.28% on Wednesday. Health care stocks were among the stronger sectors on the day, according to Commonwealth Bank’s market wrap.
On the chart, 4DMedical has traded as high as A$4.84 so far this year, after a sharp run since mid-December. Traders will watch whether the stock can hold recent gains near A$4.50 and whether it retests A$4.84 on follow-through buying.
But the company did not disclose the value of the UCSD arrangement, and the initial launch pricing limits near-term revenue visibility. Hospital rollouts can take months to expand beyond early users, and a slower conversion to full commercial terms could temper expectations.
